Oculis Holding AG (NASDAQ:OCS) Receives $33.67 Average PT from Analysts

Posted by on Oct 20th, 2023

Oculis Holding AG (NASDAQ:OCS – Get Free Report) has earned an average recommendation of “Buy” from the eight ratings firms that are currently covering the firm, MarketBeat reports. Eight analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $33.67.

Several research firms recently issued reports on OCS. Stifel Nicolaus began coverage on shares of Oculis in a research report on Wednesday, October 4th. They issued a “buy” rating and a $35.00 price target for the company. Bank of America raised their price objective on shares of Oculis from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Tuesday, August 29th. HC Wainwright reaffirmed a “buy” rating and set a $29.00 price objective on shares of Oculis in a report on Wednesday, August 30th. Finally, Robert W. Baird raised their price objective on shares of Oculis from $58.00 to $64.00 in a report on Wednesday, August 9th.

Read Our Latest Research Report on OCS

Hedge Funds Weigh In On Oculis

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Nan Fung Group Holdings Ltd bought a new position in Oculis in the first quarter valued at approximately $4,838,000. Compagnie Lombard Odier SCmA bought a new position in Oculis in the first quarter valued at approximately $472,000. HRT Financial LP bought a new position in Oculis in the first quarter valued at approximately $178,000. Ergoteles LLC bought a new position in Oculis in the second quarter valued at approximately $247,000. Finally, Barclays PLC bought a new position in Oculis in the second quarter valued at approximately $44,000. 14.28% of the stock is owned by institutional investors.

Oculis Stock Performance

NASDAQ OCS opened at $10.00 on Tuesday. The firm has a 50-day simple moving average of $12.14 and a 200 day simple moving average of $11.75. Oculis has a twelve month low of $6.26 and a twelve month high of $14.50.

Oculis (NASDAQ:OCS – Get Free Report) last posted its quarterly earnings results on Tuesday, August 29th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The company had revenue of $0.28 million for the quarter, compared to analysts’ expectations of $0.28 million. As a group, sell-side analysts expect that Oculis will post -2.91 earnings per share for the current fiscal year.

Oculis Company Profile

(Get Free Report

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Read More

Analyst Recommendations for Oculis (NASDAQ:OCS)

Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.